MedPath

Regenity Biosciences' RejuvaKnee Implant Receives FDA Clearance for Meniscal Repair

• Regenity Biosciences has received FDA 510(k) clearance for RejuvaKnee, a regenerative implant for soft tissue injuries of the meniscus, offering a minimally invasive, collagen-based approach. • Animal studies demonstrated that RejuvaKnee facilitated significant tissue regeneration, allowing full weight bearing within three months, surpassing outcomes of meniscectomy and allograft transplantation. • The RejuvaKnee implant promotes comprehensive recovery by supporting the regeneration of native meniscal tissue, potentially extending the longevity of knees affected by meniscal injuries. • Regenity Biosciences estimates a potential market of over $900 million for RejuvaKnee and seeks a strategic partner to commercialize the device in the U.S.

Regenity Biosciences has announced FDA 510(k) clearance for its RejuvaKnee implant, a novel approach to treating soft tissue injuries of the meniscus. This minimally invasive, collagen-based implant aims to reinforce and repair damaged meniscal tissue by facilitating regeneration rather than removal or replacement.

RejuvaKnee: A Regenerative Approach to Meniscal Repair

The RejuvaKnee implant represents a significant advancement in the treatment of meniscal injuries. Unlike traditional meniscectomy, which can lead to further surgeries and a predisposition to osteoarthritis, RejuvaKnee is designed to promote the regeneration of native meniscal tissue, potentially extending the life of the knee. The implant, derived from natural bovine collagen, encourages tissue ingrowth and repair.

Pre-clinical Evidence Supports Tissue Regeneration

In a 12-month animal study, RejuvaKnee demonstrated promising results. Within three months, the regenerated meniscus could withstand full weight bearing, and knee function returned to a normal range of motion. Histological analysis revealed healthy tissue regeneration, with RejuvaKnee facilitating nearly five times more tissue growth compared to the standard of care. These results suggest that RejuvaKnee offers a superior outcome compared to meniscectomy and allograft transplantation.

Clinical Implications and Market Potential

With over one million meniscectomies performed annually in the United States, the market potential for RejuvaKnee is substantial, estimated to exceed $900 million. The device is indicated for a significant portion of these procedures. Regenity Biosciences is actively seeking a strategic partner to commercialize RejuvaKnee in the U.S., bringing this innovative regenerative solution to a broad patient population.

Executive Perspective

"The FDA clearance of RejuvaKnee represents a turning point in the meniscal repair market and marks an exciting innovation milestone for Regenity as a global leader in regenerative medicine solutions," said Shawn McCarthy, CEO of Regenity Biosciences. "The pre-clinical animal study data supports our confidence that RejuvaKnee will deliver results by facilitating significant tissue regeneration and balanced implant resorption. As the only FDA-cleared regenerative implant device for meniscal repair on the market, this is a game changer for the industry."
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

NextBioMedical's Nexsphere-F Receives FDA IDE Approval for Knee Osteoarthritis Trial

NextBioMedical's Nexsphere-F has received FDA IDE approval for a clinical trial (RESORB) to treat knee osteoarthritis via genicular artery embolization (GAE).
The RESORB trial is a multi-center, randomized, open-label study evaluating Nexsphere-F's efficacy in alleviating pain and improving mobility in OA patients.

AngioDynamics' NanoKnife System Receives FDA Clearance for Prostate Tissue Ablation

AngioDynamics has received FDA clearance for its NanoKnife System for prostate tissue ablation, marking a significant advancement in minimally invasive cancer treatment.
The PRESERVE clinical study demonstrated that 84% of men were free from clinically significant prostate cancer 12 months post-procedure using the NanoKnife System.

Maxx Orthopedics Gains FDA Clearance for Medial Congruent Insert in Total Knee Arthroplasty

Maxx Orthopedics has received FDA clearance for its medial congruent insert designed for use with the Freedom total knee arthroplasty system.
The new insert aims to replicate natural knee kinematics and enhance medial stability for patients undergoing total knee arthroplasty.

Exactech Receives FDA Clearance for Truliant Porous 3D Tibial Knee Implant

Exactech's Truliant porous 3D tibial tray received FDA 510(k) clearance, marking a significant advancement in cementless knee replacement solutions.
The implant utilizes additive manufacturing to create a porous structure that mimics cancellous bone, promoting initial and biological fixation for active patients.

Exactech's Truliant Porous 3D Tibial Implant Receives FDA Clearance for Knee Replacement

Exactech has secured FDA 510(k) clearance for its Truliant® Porous 3D Tibial Tray, an innovative 3D-printed tibial knee implant designed for cementless fixation.
The Truliant Porous implant mimics cancellous bone structure, promoting initial and biological fixation, catering to active patients needing total knee arthroplasty.

Nature Cell's JointStem Receives FDA RMAT Designation for Severe Osteoarthritis

Nature Cell's JointStem, a stem cell therapy for severe degenerative arthritis, has been granted RMAT designation by the FDA.
The RMAT designation expedites the development and approval process for regenerative treatments targeting serious diseases with unmet medical needs.

Corin's Unity Knee Medial Constrained Tibial Insert Receives FDA Clearance for TKA

Corin has received FDA 510(k) clearance for its Unity Knee medial constrained tibial insert, designed for both standard and robotic-assisted total knee arthroplasty (TKA).
The Unity Knee MC insert is compatible with Corin's ApolloKnee robotic platform, allowing surgeons to stabilize the medial compartment during TKA procedures.

FDA Approves Arthroscopic Delivery for MACI Knee Cartilage Repair

The FDA has approved a supplemental Biologics License Application for arthroscopic delivery of MACI, an autologous cultured chondrocytes on a porcine collagen membrane, for knee cartilage repair.
This approval expands MACI's delivery options, offering a less invasive arthroscopic approach for repairing symptomatic cartilage defects up to 4 cm2.

THINK Surgical's TMINI Robot Cleared for Zimmer Biomet's Persona Knee System

THINK Surgical received FDA 510(k) clearance for its TMINI robotic system to be used with Zimmer Biomet's Persona Knee System, expanding surgical options.
The TMINI system features a wireless, handheld design intended to enhance precision in total knee replacement procedures, particularly in outpatient settings.

FDA Clears IND for Myogenica's MyoPAXon in Duchenne Muscular Dystrophy

Myogenica, a University of Minnesota startup, received FDA clearance for its IND application for MyoPAXon, a stem cell therapy for muscular regeneration.
The planned clinical trial will assess the safety, tolerability, and engraftment of MyoPAXon in adult patients with Duchenne muscular dystrophy (DMD).

Reference News

[1]
Regenerative Bioscience's meniscus implant receives FDA clearance
medicaldevice-network.com · Oct 9, 2024

Regenity Biosciences received FDA 510(k) clearance for its RejuvaKnee meniscus implant, designed for minimally invasive,...

[2]
FDA clears Regenity Biosciences' regenerative meniscus implant - MassDevice
massdevice.com · Oct 9, 2024

Regenity Biosciences received FDA 510(k) clearance for its RejuvaKnee implant, designed for meniscus soft tissue injurie...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy